Navigation Links
Board Reviews Strategic Options to Present to Shareholders at Shareholders' Meeting

REINACH, Switzerland, March 17 /PRNewswire-FirstCall/ -- In their press release of 25 February 2009, Arpida communicated that the Board of Directors was in the process of reviewing all the options for the company's future.

In preparation of the shareholders' meeting on 7 May 2009, the Board wishes to update shareholders as follows: At the shareholders' meeting, the Board plans to present all available strategic choices, which could include the following options or a combination thereof:

    - reverse merger with another biotech business
    - selling iclaprim and related assets
    - tender offer for the entire company
    - other options, including a return of capital

The Board believes that the currently depressed stock market may value the company as a whole less than the sum of its assets. It will therefore invite Arpida shareholders to select their preferred strategic option at the shareholders' meeting on 7 May 2009.

The invitation and agenda for the AGM will be available from 15 April 2009.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.


    Dr Jurgen Raths, President and CEO
    Tel.: +41-61-417-96-60

    Harry Welten, MBA, CFO and Senior Vice President
    Tel.: +41-61-417-96-65

    Paul Verbraeken, Head of Corporate Communications
    Tel.: +41-61-417-96-83

SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. KGI Elects Three New Members to Board of Trustees
3. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
4. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
5. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
6. BioLife Solutions Expands Scientific Advisory Board
7. NeurogesX Appoints New Director to the Board
8. Genstar Names Michael Hurt to Its Strategic Advisory Board
9. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
10. Bruce Pasternack Elected to Codexis Board
11. Interleukin Genetics Announces Management and Board Appointments
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... ... 2015 , ... Copper is an essential micronutrient that all ... copper is also toxic to cells. With a $1.3 million award from the ... a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), a ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader ... five states to develop and pitch their BIG ideas to improve health and wellness ... competing for votes to win the title of SAP's Teen Innovator, an all-expenses paid ...
Breaking Biology Technology:
(Date:11/18/2015)...  As new scientific discoveries deepen our understanding of ... providers face challenges in better using that knowledge to ... as more children continue to survive pediatric cancer, that ... age. John M. Maris, M.D ., a ... (CHOP) . --> John M. Maris, ...
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
Breaking Biology News(10 mins):